Schott Pharma (stylized as SCHOTT Pharma) is a provider of drug containment solutions and delivery systems for injectable drugs.[2][3] Originally a division of glass manufacturer Schott AG, the company went public on the Frankfurt Stock Exchange in 2023.[4] Headquartered in Mainz, Germany,[5][6] the company operates in 14 countries.[7]
In 1887, Otto Schott developed borosilicate glass, a form of glassware used to reagent bottles and flasks. From 1911, Schott manufactured borosilicate glass tubing for the production of pharmaceutical ampoules and vials.[8]
Schott Pharma was established as a standalone company in 2022 under the name Schott Pharma AG & Co. KGaA[9][6] through an equity carve-out (or spin-off) from Schott AG, a manufacturer of specialty glass and glass-ceramics.[10][11] In the same year, the company announced their plans to present an IPO, but this was reportedly postponed to 2023 due to the Russian invasion of Ukraine.[5]
In June 2023, Schott Pharma announced plans to hold the IPO in September 2023.[12] This plan was enacted in September, with Schott Pharma going public on the Frankfurt Stock Exchange.[13] The IPO was initially priced at €27 per share,[14][15] and a potential valuation of up to 4.1 billion euros,[16] but increased the share price to €30 the following day.[17][13] The IPO was the largest of the year in Germany.[18][19] In December 2023, Schott Pharma was included in the SDAX.[20] Between September 2024 and March 2025, it was also listed in the MDAX.[21][22]
The company is headquartered in Mainz and operates in 16 locations across 14 countries.[23]
Schott Pharma is a subsidiary of SCHOTT AG, which holds controlling shares (as of 2023: 77%).[19][17] SCHOTT AG is owned by the Carl Zeiss Foundation.[26]
Schott Pharma is listed on the Frankfurt Stock Exchange's MDAX.[21]
The supervisory board for the Schott Pharma AG is as follows:[34][35]
